Claims for Patent: 12,465,608

Summary for Patent: 12,465,608

Title:	Osimertinib for use in the treatment of non-small cell lung cancer
Abstract:	The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of EGFR TKI-naïve patients with locally-advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC), wherein the EGFR TKI is administered in combination with pemetrexed and platinum chemotherapy.
Inventor(s):	Anthony Francis Patrick NASH
Assignee:	AstraZeneca AB
Application Number:	US17/593,923
Patent Claims:	1. A method of treating locally-advanced or metastatic EGFR mutation-positive NSCLC in an EGFR TKI-naïve human patient comprising administering to the patient an EGFR TKI, wherein the EGFR TKI is administered in combination with pemetrexed and platinum chemotherapy, and wherein the EGFR TKI is osimertinib, or a pharmaceutically acceptable salt thereof. 2. The method according to claim 1, wherein the platinum chemotherapy comprises a platinum-based agent selected from cisplatin or carboplatin. 3. The method according to claim 1, wherein the pemetrexed and platinum chemotherapy are administered on day 1 only of a treatment cycle lasting 21 days. 4. The method according to claim 1, wherein the pemetrexed and platinum chemotherapy are administered on day 1 only of a treatment cycle lasting 21 days for four sequential cycles, followed by administration of pemetrexed once every 21 days until disease progression or unacceptable toxicity. 5. The method according to claim 1, wherein the EGFR mutation-positive NSCLC comprises activating mutations in EGFR selected from exon 19 deletions or L858R substitution mutations. 6. The method according to claim 1, wherein the locally-advanced or metastatic EGFR mutation-positive NSCLC is a metastatic EGFR mutation-positive NSCLC. 7. The method according to claim 1, wherein the osimertinib, or a pharmaceutically acceptable salt thereof, is administered once-daily. 8. The method according to claim 1, wherein the osimertinib, or a pharmaceutically acceptable salt thereof, is administered in tablet form. 9. The method according to claim 1, wherein the osimertinib, or a pharmaceutically acceptable salt thereof, is osimertinib mesylate salt.